123495-48-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (S)-piperidine-2-carboxylate HCl is used as an intermediate in the synthesis of various pharmaceuticals for its versatile chemical properties. It contributes to the development of new drugs and active pharmaceutical ingredients, enhancing the therapeutic potential of medications.
Used in Organic Compounds Synthesis:
Ethyl (S)-piperidine-2-carboxylate HCl is used as a key intermediate in the synthesis of organic compounds, particularly in the production of complex molecules with specific functionalities. Its unique structure and reactivity make it a valuable building block for creating novel organic molecules with diverse applications.
Used in Chemical Reactions and Processes:
Ethyl (S)-piperidine-2-carboxylate HCl is used in various chemical reactions and processes due to its enhanced solubility and stability. It serves as a catalyst or a reactant in the synthesis of other compounds, facilitating the formation of desired products and improving the efficiency of chemical processes.

Upstream product

• 64-17-5 ethanol 
• 3105-95-1 pipecolinic acid 
• 1258422-24-0 ethyl (S)-1-[(S)-1-phenylethyl]-1,2,3,6-tetrahydropyridine-2-carboxylate 
• 1258422-16-0 ethyl 2-{allyl[(S)-1-phenylethyl]amino}pent-4-enoate 

Downstream Products

• 123495-49-8 (2S,αS)-α-(Benzyloxycarbonylamino)-2-ethoxycarbonyl-1-piperidin-butansaeure-tert-butylester 
• 3105-95-1 pipecolinic acid 
• 123518-90-1 (2S,αS)-α<(3S)-(3-Benzyloxycarbonylamino-3-tert-butyloxycarbonyl)propylamino>-2-ethoxycarbonyl-1-piperidinbutansaeure-tert-butylester 

Relevant academic research and scientific papers

Synthesis of enantiopure cyclic amino acid derivatives via a sequential diastereoselective Petasis reaction/ring closing olefin metathesis process

A novel approach to the synthesis of enantiopure cyclic amino esters is reported. The utilization of allylboronic acid together with (S)-α-methylbenzylamine as a chiral auxiliary in the Petasis/Mannich reaction led to the formation of allylglycine derivatives in good yield and with high diastereoselectivity. Subsequent esterification, N-allylation followed by ring-closing metathesis (RCM) reaction enabled the preparation of enantiomerically pure cyclic α-amino acid derivatives.

Synthesis of non-natural cyclic amino acids from available unsaturated tertiary amines

New approach is developed to the synthesis of cyclic amino acids derivatives. Unsaturated tertiary amines react with ethyl diazoacetate under the catalysis by copper catalyst Cu(F3acac)2 leading to the formation of products of [2,3]-sigmatropic rearrangement which via the metathesis of double bonds undergo a ring closure. The subsequent hydrogenation of compounds obtained furnished esters of 6- and 7-membered cyclic α-amino acids. Besides the racemic also optically active compounds were obtained, in particular, esters of (R)- and (S)-pipecolic acid.

A concise synthesis of (±) and a total synthesis of (+)-epiquinamide

A total synthesis of the quinolizidine alkaloid (+)-epiquinamide 1 has been achieved starting from (-)-pipecolinic acid 3. The key step is the highly diastereoselective addition of a TBDMS-protected propargyl alcohol to a chiral aldehyde derived from 3 to give erythro alkynol 19, which is then easily transformed into the desired bicyclic skeleton.

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.